For US Healthcare Professionals
I am a
Rheumatology Specialist
For US Healthcare Professionals
Full Prescribing Information
Sign-up Portal
Explore coverage options in your area
View Covered Medicare Part D Plans
Download
Collected in 01/25 and subject to change. This information does not provide advice or guarantee coverage or payment. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply.
Source: Managed Markets Insight & Technology, LLCTM, a trademark of MMIT, as of January 2025.
*These percentages may not represent 100% of formulary lives due to data limitations.
†“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class. Source: Data on file, Jansen Biotech, Inc., as of 11/24 and may change.
‡Requiring no step edits indicates a drug will be given first-line biologic access and will not require stepping through other biologic therapies.
§“Superior” means the number of first-line covered lives is at least 10% greater for TREMFYA® than for Cosentyx® (secukinumab), Taltz® (ixekizumab) and Humira® (adalimumab).
§“Superior” means the number of first-line covered lives is at least 10% greater for TREMFYA® than for Cosentyx® [secukinumab], Taltz® [ixekizumab], and Humira® [adalimumab].
IIThe information provided does not imply comparable safety or efficacy between products and only represents access information. Indicated trademarks are the registered trademarks of their respective owners. Please refer to each product’s prescribing information for indication(s), recommended dosing, and administration.
¶“Majority” means 51-65% number of covered lives.
Source: Data on file, Jansen Biotech, Inc., as of 11/24 and may change.
